In this study, 14 patients with urinary tract infection and 8 patients with respiratory tract infection were given 400 mg/day of ofloxacin. 12 of 14 patients with urinary tract infection and 4 of 8 patients with respiratory tract infection was cured and clinically improved. 12 of 13 E. coli isolates were eradicated with this treatment. No severe adverse reactions were observed. No in vitro resistance against ofloxacin was seen.